KemPharm found using ticker (KMPH) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 28 and 24 and has a mean target at 26. With the stocks previous close at 9.32 this is indicating there is a potential upside of 179.0%. The 50 day moving average now sits at 7.82 while the 200 day moving average is 10.33. The market cap for the company is $205m. Company Website: http://kempharm.com
KemPharm, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.